LABORATORIO REIG JOFRE (ES:RJF) has released an update.
Reig Jofre, a pharmaceutical company listed on the Spanish stock exchange, has reported a robust financial performance for Q3 2024, with a 7% rise in revenues and a 10% increase in EBITDA, driven by international market growth and investments in industrial capacity. The company’s operating profit surged by 22%, supported by the success of its Specialty Pharmacare and Pharmaceutical Technologies divisions, alongside strategic investments totaling €13.6 million. Despite inflationary pressures, the company maintained a stable debt/EBITDA ratio and anticipates continued profitability through its global expansion and product optimization strategies.
For further insights into ES:RJF stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
